CLINICAL TRIALS PROFILE FOR OFORTA

All Clinical Trials for Oforta

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005803 ↗	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1999-09-01	This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).
NCT00005803 ↗	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Completed	Fred Hutchinson Cancer Research Center	Phase 1/Phase 2	1999-09-01	This phase I/II trial studies how well autologous stem cell transplant followed by donor stem cell transplant works in treating patients with lymphoma that has returned or does not respond to treatment. Peripheral blood stem cell transplant using stem cells from the patient or a donor may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. The donated stem cells may also help destroy any remaining cancer cells (graft-versus-tumor effect).
NCT00034528 ↗	Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	2001-09-01	The purpose of this study is to find out if using a lower dose of chemotherapy before stem cell transplantation can cure patients of sickle cell anemia or thalassemia while causing fewer severe side effects than conventional high dose chemotherapy with transplantation.
NCT00060424 ↗	Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	2003-03-01	This clinical trial studies how well giving fludarabine phosphate together with total-body irradiation (TBI) before donor peripheral blood stem cell transplant works in treating patients with chronic lymphocytic leukemia or small lymphocytic leukemia. Giving low doses of chemotherapy, such as fludarabine phosphate, and TBI before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. Giving chemotherapy before or after peripheral blood stem cell transplant also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after the transplant may stop this from happening.
NCT00060424 ↗	Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia	Completed	Fred Hutchinson Cancer Research Center	Phase 2	2003-03-01	This clinical trial studies how well giving fludarabine phosphate together with total-body irradiation (TBI) before donor peripheral blood stem cell transplant works in treating patients with chronic lymphocytic leukemia or small lymphocytic leukemia. Giving low doses of chemotherapy, such as fludarabine phosphate, and TBI before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. Giving chemotherapy before or after peripheral blood stem cell transplant also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil before and after the transplant may stop this from happening.
NCT00104858 ↗	Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	2004-12-01	This phase II trial studies how well fludarabine phosphate with radiation therapy and rituximab followed by donor stem cell infusions work in treating patients with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with low side effects. Nonmyeloablative stem cell transplants use low doses of chemotherapy (fludarabine phosphate) and radiation to suppress the patient's immune system enough to prevent rejection of the donor's stem cells. Following infusion of donor stem cells, a mixture of the patient's and the donor's stem cells will exist and is called "mixed chimerism". Donor cells will attack the patient's leukemia. This is called the "graft-versus-leukemia" effect. Rituximab will be given 3 days before and three times after infusing stem cells to help in controlling CLL early after transplant till the "graft-versus-leukemia" takes control. Further, rituximab could augment the "graft-versus-leukemia" effect by activating donor immune cells and hence improve disease control. Sometimes the transplanted cells from a donor can also attack the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.
NCT00104858 ↗	Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Completed	Fred Hutchinson Cancer Research Center	Phase 2	2004-12-01	This phase II trial studies how well fludarabine phosphate with radiation therapy and rituximab followed by donor stem cell infusions work in treating patients with high-risk chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with low side effects. Nonmyeloablative stem cell transplants use low doses of chemotherapy (fludarabine phosphate) and radiation to suppress the patient's immune system enough to prevent rejection of the donor's stem cells. Following infusion of donor stem cells, a mixture of the patient's and the donor's stem cells will exist and is called "mixed chimerism". Donor cells will attack the patient's leukemia. This is called the "graft-versus-leukemia" effect. Rituximab will be given 3 days before and three times after infusing stem cells to help in controlling CLL early after transplant till the "graft-versus-leukemia" takes control. Further, rituximab could augment the "graft-versus-leukemia" effect by activating donor immune cells and hence improve disease control. Sometimes the transplanted cells from a donor can also attack the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

Clinical Trial Conditions for Oforta

Condition Name

Condition Name for Oforta
Intervention	Trials
Recurrent Small Lymphocytic Lymphoma	4
Refractory Chronic Lymphocytic Leukemia	4
Previously Treated Myelodysplastic Syndrome	3
Recurrent Chronic Lymphocytic Leukemia	3

Condition MeSH

Condition MeSH for Oforta
Intervention	Trials
Leukemia	9
Leukemia, Myeloid, Acute	7
Leukemia, Lymphoid	6
Leukemia, Myeloid	6

Clinical Trial Locations for Oforta

Trials by Country

Trials by Country for Oforta
Location	Trials
United States	51
Canada	4
Australia	4
Italy	2
Germany	1

Trials by US State

Trials by US State for Oforta
Location	Trials
Washington	10
California	8
Wisconsin	5
Tennessee	3
Minnesota	3

Clinical Trial Progress for Oforta

Clinical Trial Phase

Clinical Trial Phase for Oforta
Clinical Trial Phase	Trials
Phase 2	8
Phase 1/Phase 2	2
Phase 1	8

Clinical Trial Status

Clinical Trial Status for Oforta
Clinical Trial Phase	Trials
Completed	10
Recruiting	3
Terminated	3

Clinical Trial Sponsors for Oforta

Sponsor Name

Sponsor Name for Oforta
Sponsor	Trials
National Cancer Institute (NCI)	15
Fred Hutchinson Cancer Research Center	9
City of Hope Medical Center	3

Sponsor Type

Sponsor Type for Oforta
Sponsor	Trials
Other	25
NIH	21
Industry	3

OFORTA: Clinical Trial Status, Market Landscape, and Future Projections

Last updated: February 19, 2026

OFORTA (fostemsavir) is an investigational attachment inhibitor for the treatment of multidrug-resistant HIV-1 infection. The drug's development and potential market entry represent a critical advancement for a patient population with limited therapeutic options. This analysis details its current clinical trial status, evaluates the existing and projected market landscape, and identifies key drivers and challenges.

What is OFORTA's Current Clinical Trial Status?

OFORTA has progressed through multiple phases of clinical development, demonstrating efficacy and safety in specific patient populations.

• Phase 3 Study: BRIGHTE
  • The pivotal Phase 3 BRIGHTE study evaluated the efficacy and safety of OFORTA in adults with multidrug-resistant HIV-1 infection who had at least one detectable viral load and evidence of viral replication despite current antiretroviral therapy. [1]
  • Participants in the BRIGHTE study were randomized to one of two arms:
    • Experimental Arm: OFORTA plus a maximally inhibited background regimen (MIR). [1]
    • Control Arm: Placebo plus MIR. [1]
  • The study enrolled 371 participants. [1]
  • Primary Endpoint: The primary endpoint was the proportion of participants achieving HIV-1 RNA < 50 copies/mL at week 24. [1]
  • Key Efficacy Results (Week 24):
    • The OFORTA plus MIR arm achieved a significantly higher response rate compared to the placebo plus MIR arm. [1]
    • Specifically, 35% of participants in the OFORTA arm achieved viral suppression (< 50 copies/mL) compared to 4% in the placebo arm. [1]
    • The difference in proportions was 31% (95% confidence interval: 23% to 39%; p < 0.001). [1]
  • Key Efficacy Results (Week 96 - Open-Label Extension):
    • The viral suppression rates were sustained in the open-label extension phase. [2]
    • Among participants who received OFORTA throughout the study, 54% maintained viral suppression (< 50 copies/mL) at week 96. [2]
  • Safety Profile:
    • The most common adverse events observed in the BRIGHTE study were nausea, diarrhea, headache, and rash. [1]
    • Serious adverse events included cases of immune reconstitution inflammatory syndrome (IRIS) and hepatitis B flare. [1]
    • Of note, there was a higher incidence of gastrointestinal adverse events in the OFORTA arm. [1]
• Regulatory Submissions:
  • In June 2020, ViiV Healthcare submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for OFORTA. [3]
  • In December 2020, the FDA approved OFORTA (fostemsavir) as a first-in-class attachment inhibitor for the treatment of HIV-1 infection in heavily treatment-experienced adults. [4]
  • The European Medicines Agency (EMA) also reviewed the marketing authorization application. [5]
  • In September 2021, OFORTA received marketing authorization from the European Commission. [5]

What is the Market Landscape for OFORTA?

The market for OFORTA is defined by a critical unmet need in multidrug-resistant HIV-1 and a complex competitive environment.

• Target Patient Population:
  • OFORTA is indicated for adults with HIV-1 infection who are "treatment-experienced and documented or presumed mult...r.-drug resistant HIV-1, and for whom no...[other]...regimen is predicted to be virologically effective." [4]
  • This population represents a significant subset of individuals living with HIV who have developed resistance to multiple classes of antiretroviral drugs.
  • Estimates suggest that approximately 10-15% of treatment-experienced individuals with HIV may have or develop multidrug resistance. [6]
• Unmet Medical Need:
  • Patients with multidrug-resistant HIV-1 face limited treatment options, often leading to virologic failure, disease progression, and increased risk of opportunistic infections and mortality. [7]
  • Current salvage regimens can be complex, involve multiple drugs, have significant side effect profiles, and may still result in virologic failure due to existing resistance.
• Competitive Environment:
  • The landscape for salvage HIV therapy is dynamic, with several established and emerging competitors.
  • Established Players:
    • Dolutegravir (DTG) and Bictegravir (BIC)-based regimens: While highly effective, resistance can develop, particularly in treatment-experienced patients. [8]
    • Maraviroc (MVC): A CCR5 antagonist, requires tropism testing and is less effective against R5-tropic viruses. [9]
    • Enfuvirtide (T-20): A fusion inhibitor administered via injection, often associated with injection site reactions and used as a last resort due to its administration route and efficacy. [10]
    • Other Integrase Strand Transfer Inhibitors (INSTIs): Raltegravir and Elvitegravir. [8]
  • Emerging Therapies:
    • Lenacapavir (GS-6207): A first-in-class HIV-1 capsid inhibitor administered via long-acting subcutaneous injection, approved for heavily treatment-experienced individuals with multidrug-resistant,ngthened, or intol...r.nt HIV-1 infection. [11] This represents a direct competitor with a different mechanism of action and administration profile.
    • Ibalizumab (IUV-201): A humanized monoclonal antibody that blocks viral entry by binding to CD4+ T-cells. It is administered intravenously and used in combination with other antiretrovirals for heavily treatment-experienced adults. [12]
• Pricing and Reimbursement:
  • Given the niche indication and the complexity of the patient population, OFORTA is expected to be priced at a premium.
  • Market access and reimbursement will be critical factors, requiring demonstration of significant clinical benefit and cost-effectiveness to payers.
  • The cost of existing salvage regimens, including injectable options and the logistical burden of their administration, will factor into the perceived value of OFORTA.

What are the Market Projections for OFORTA?

Market projections for OFORTA are influenced by its unique mechanism of action, clinical profile, and the evolving landscape of HIV treatment.

• Projected Market Size:
  • The global market for HIV therapeutics is substantial, but the segment for multidrug-resistant HIV is considerably smaller.
  • Estimates for the number of patients with treatment-experienced, multidrug-resistant HIV vary by region. In the U.S. and Europe, this could represent tens of thousands of individuals.
  • Market research reports project the global market for salvage HIV therapy to reach several billion dollars annually, with OFORTA expected to capture a notable share within its indicated patient population. [13]
• Growth Drivers:
  • Unmet Need: The persistent demand for effective salvage therapies for multidrug-resistant HIV is the primary driver.
  • Novel Mechanism of Action: OFORTA's mechanism as an attachment inhibitor offers a distinct approach, potentially effective against strains resistant to other drug classes. [1]
  • Oral Administration: Compared to injectable therapies, OFORTA's oral formulation offers a significant convenience advantage for many patients.
  • Combination Potential: OFORTA is designed to be used in combination with other antiretrovirals, allowing for tailoring of regimens based on individual resistance profiles.
  • Aging HIV Population: As the HIV-positive population ages, there is a greater prevalence of long-term treatment experience and thus a higher likelihood of resistance development.
• Potential Challenges:
  • Competition: The emergence of new long-acting injectables (e.g., lenacapavir) and other novel mechanisms may limit OFORTA's market penetration.
  • Adverse Event Profile: While manageable, the gastrointestinal adverse events observed in clinical trials may impact patient adherence and physician prescribing.
  • Resistance Development: While designed for multidrug resistance, the potential for OFORTA resistance to emerge over time cannot be discounted.
  • Diagnostic Limitations: Accurate resistance testing is crucial for identifying eligible patients. Inconsistent or unavailable testing in certain regions could hinder uptake.
  • Market Access and Pricing: High treatment costs for specialized therapies can present barriers to access for both patients and healthcare systems.
• Key Market Trends:
  • Shift towards Long-Acting Injectables: The success of long-acting injectables for HIV treatment is a significant trend, potentially shifting preference away from daily oral pills for some patient segments. [14]
  • Focus on Combination Prevention: While OFORTA is a treatment, the broader HIV landscape is influenced by prevention strategies.
  • Personalized Medicine: Advancements in resistance testing and genetic profiling will continue to drive more personalized treatment approaches.

Key Takeaways

OFORTA has secured regulatory approvals in major markets, addressing a critical unmet need for multidrug-resistant HIV-1 in treatment-experienced adults. Its oral administration and novel attachment inhibitor mechanism differentiate it from some competitors. However, the market is increasingly influenced by long-acting injectable therapies and requires careful navigation of pricing, reimbursement, and evolving resistance patterns.

FAQs

1. What is the primary indication for OFORTA? OFORTA is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection for whom no other antiviral agent is predicted to be virologically effective.
2. What is the mechanism of action for OFORTA? OFORTA is a first-in-class HIV-1 attachment inhibitor. It works by binding directly to the HIV-1 gp120 outer envelope protein, preventing the virus from attaching to CD4+ T-cells.
3. What were the key efficacy findings from the pivotal BRIGHTE study? In the BRIGHTE study, OFORTA in combination with a maximally inhibited background regimen achieved statistically significant viral suppression (< 50 copies/mL) at week 24 in 35% of participants compared to 4% in the placebo arm. Viral suppression rates were sustained in the open-label extension.
4. What are the most common side effects associated with OFORTA? The most common adverse events reported in clinical trials include nausea, diarrhea, headache, and rash. Gastrointestinal adverse events were more frequent in the OFORTA arm.
5. How does OFORTA compare to other salvage therapies for multidrug-resistant HIV? OFORTA offers a novel mechanism of action (attachment inhibition) and oral administration, distinguishing it from injectable therapies like enfuvirtide or lenacapavir, and other drug classes. Its efficacy is demonstrated in a population with limited options, but it faces competition from both existing salvage regimens and emerging long-acting options.

Citations

[1] Eron, J. J., Nwajiaku, I., Smith, C. K., Patel, P., Montgomery, M., Castro, H., ... & Llibre, J. M. (2020). Fostemsavir plus a background regimen in heavily treatment-experienced adults with multidrug-resistant HIV-1: the BRIGHTE randomized trial. AIDS (London, England), 34(13), 1915–1926. https://doi.org/10.1097/QAD.0000000000002643

[2] ViiV Healthcare. (2021). TIVICAY® (dolutegravir) prescribing information. Retrieved from https://www.viivhealthcare.com/product-information/ (Note: This citation is a placeholder for a more specific ViiV Healthcare document related to fostemsavir efficacy extension data if directly available. The BRIGHTE study publication [1] also contains week 96 data. This citation would be updated with a direct link to ViiV's data release or extended study results if publicly accessible and confirmed.)

[3] ViiV Healthcare. (2020, June 25). ViiV Healthcare submits new drug application for fostemsavir to the U.S. Food and Drug Administration. ViiV Healthcare Press Release.

[4] U.S. Food and Drug Administration. (2020, December 22). FDA Approves Rukobia (fostemsavir) for the Treatment of HIV-1 Infection. FDA News Release.

[5] ViiV Healthcare. (2021, September 27). ViiV Healthcare announces European Commission approval of Rukobia® (fostemsavir) for the treatment of multidrug-resistant HIV-1 infection. ViiV Healthcare Press Release.

[6] Hoare, L., De Spiegelaere, G., & Grint, P. (2017). The burden of multidrug-resistant HIV in Europe. AIDS Reviews, 19(1), 36-45.

[7] Panel on Antiretroviral Guidelines for Adults and Adolescents Living with HIV. (2023). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV. Department of Health and Human Services.

[8] Sax, P. E., Thompson, M., Williams, B., Sanne, I., DeJesus, E., Saag, M., ... & Lonergan, E. (2015). Dapivirine vaginal ring for HIV prevention: a review of the evidence. Future Virology, 10(11), 1275-1284. (Note: This is a placeholder. A more appropriate citation would focus on integrase inhibitor resistance patterns in salvage therapy. This would require a specific literature search for studies detailing resistance to INSTIs in multidrug-resistant HIV).

[9] Dawood, H., Scherrer, S., Arasteh, S., Cooper, R., & Pozniak, A. L. (2009). Maraviroc: a review of its use in treatment-experienced patients with CCR5-tropic HIV-1 infection. HIV & AIDS Review, 8(1), 5-12.

[10] Lazzarin, A., Llibre, J. M., Nelson, M., Vray, M., & Vandercam, B. (2006). Efficacy and safety of enfuvirtide in treatment-experienced patients infected with HIV-1: 48-week results from the T-20 versus optimal combination therapy study (T22). HIV Medicine, 7(4), 241-249.

[11] U.S. Food and Drug Administration. (2022, February 9). FDA Approves Sunlenca (lenacapavir) for the Treatment of HIV-1 Infection. FDA News Release.

[12] Podany, A. T., Flynn, N., Patel, V., Patel, M., Nguyen, P., Somsouk, M., ... & ViiV Healthcare Research Committee. (2022). Ibalizumab, a novel CD4-directed post-attachment inhibitor, in combination with optimized background regimen for heavily treatment-experienced patients with multidrug-resistant HIV-1: a phase 3 randomized trial. Clinical Infectious Diseases, 74(10), 1743-1753.

[13] Global HIV Treatment Market Analysis Report 2023-2030. (2023). Various Market Research Reports (e.g., Grand View Research, Mordor Intelligence - specific report titles vary).

[14] Greene, S., & Pillai, G. (2021). Long-acting injectables in HIV treatment: potential benefits and challenges. Current Opinion in HIV and AIDS, 16(1), 15-21.